Biohope Welcomes Virginia González as New Chief Executive Officer
Biohope is glad to announce the appointment of Virginia González as its new Chief Executive Officer, marking an important milestone in the company’s evolution after more than ten years of growth and scientific consolidation.
As CEO, Virginia González will lead Biohope into its next phase of development, with a strong focus on accelerating the company’s commercial development, expanding market presence, and strengthening strategic partnerships. Her leadership will build on Biohope’s solid scientific foundation while driving sustainable growth and transforming innovation into broader clinical and commercial impact.
Following this transition, Isabel Portero, Founder and former Chief Executive Officer of Biohope, will continue with the company as Chief Scientific Officer (CSO). In this role, she will remain responsible for leading Biohope’s scientific and strategic vision, ensuring continuity and excellence in research, innovation, and clinical development.
“We are delighted to welcome Virginia González as CEO of Biohope,” said Isabel. “Her leadership, vision, and strong business focus align perfectly with our current stage and long-term strategy. We are confident that this new chapter will further strengthen Biohope’s position as a leader in precision medicine.”
This leadership evolution reflects Biohope’s maturity as an organization and reinforces its commitment to combining scientific excellence with commercial growth. The entire Biohope team warmly welcomes Virginia González and looks forward to this new phase, continuing to deliver innovative solutions that bring hope to patients and clinicians worldwide.
